References
- Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., & Moss, A. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. Aids (London, England), 15(9), 1181–1183. https://doi.org/10.1097/00002030-200106150-00015
- Benítez-Gutiérrez, L., Soriano, V., Requena, S., Arias, A., Barreiro, P., & de Mendoza, C. (2018). Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert Review of Clinical Pharmacology, 11(5), 507–517. https://doi.org/10.1080/17512433.2018.1453805
- Bowling, A. (2005). Just one question: If one question works, why ask several? Journal of Epidemiology & Community Health, 59(5), 342–345. https://doi.org/10.1136/jech.2004.021204
- Calder, B. J., Schieffer, R. J., Bryndza Tfaily, E., D’Aquila, R., Greene, G. J., Carballo-Diéguez, A., Giguere, R., Kiser, P. F., & Hope, T. J. (2018). Qualitative consumer research on acceptance of long-acting pre-exposure prophylaxis products among men having sex with men and medical practitioners in the United States. AIDS Research and Human Retroviruses, 34(10), 849–856. https://doi.org/10.1089/AID.2018.0214
- Centers for Disease Control and Prevention. HIV Surveillance. 2016; vol. 28. (2017). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
- Chen, J., Walters, K., & Ashton, P. (2005). Correlation of in vitro-in vivo release rates for sustained release nevirapine implants in rats. Journal of Controlled Release, 101(1-3), 357–358.
- Curtis, K. M., Jatlaoui, T. C., Tepper, N. K., Zapata, L. B., Horton, L. G., Jamieson, D. J., & Whiteman, M. K. (2016). U.S. Selected practice recommendations for contraceptive use, 2016. MMWR. Recommendations and Reports, 65(4), 1–66. https://doi.org/10.15585/mmwr.rr6504a1
- Dawson, D. A., Grant, B. F., Stinson, F. S., & Zhou, Y. (2005). Effectiveness of the derived alcohol use disorders identification test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. Alcoholism: Clinical & Experimental Research, 29(5), 844–854. https://doi.org/10.1097/01.ALC.0000164374.32229.A2
- Dolgin, E. (2014). Long-acting HIV drugs advanced to overcome adherence challenge. Nature Medicine, 20(4), 323–324. https://doi.org/10.1038/nm0414-323
- Doswell, W. M., Braxter, B. J., Cha, E., & Kim, K. H. (2011). Testing the theory of reasoned action in explaining sexual behavior among African American young teen girls. Journal of Pediatric Nursing, 26(6), e45–e54. https://doi.org/10.1016/j.pedn.2011.03.007
- Emu, B., Fessel, J., Schrader, S., Kumar, P., Richmond, G., Win, S., Weinheimer, S., Marsolais, C., & Lewis, S. (2018). Phase 3 study of ibalizumab for multidrug-resistant HIV-1. New England Journal of Medicine, 379(7), 645–654. https://doi.org/10.1056/NEJMoa1711460
- FDA. (2018). Drug approval and databases. Drug approval package TROGARZO injection: Ibaluzimab. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/TROGARZO_761065_TOC.cfm
- Flexner, C., Thomas, D. L., & Swindells, S. (2019). Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. Current Opinion in HIV and AIDS, 14(1), 13–20. https://doi.org/10.1097/COH.0000000000000510
- Gardner, L. I., Marks, G., Shahani, L., Giordano, T. P., Wilson, T. E., Drainoni, M. L., Keruly, J. C., Batey, D. S., & Metsch, L. R. (2016). Assessing efficacy of a retention-in-care intervention among HIV patients with depression, anxiety, heavy alcohol consumption and illicit drug use. Aids (london, England), 30(7), 1111–1119. https://doi.org/10.1097/QAD.0000000000001019
- Granich, R., Gupta, S., Hall, I., Aberle-Grasse, J., Hader, S., & Mermin, J. (2017). Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review. PLOS Medicine, 14(4), e1002253. https://doi.org/10.1371/journal.pmed.1002253
- Greene, G. J., Swann, G., Fought, A. J., Carballo-Diéguez, A., Hope, T. J., Kiser, P. F., Mustanski, B., & D’Aquila, R. T. (2017). Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS and Behavior, 21(5), 1336–1349. https://doi.org/10.1007/s10461-016-1565-9
- Gunawardana, M., Remedios-Chan, M., Miller, C. S., Fanter, R., Yang, F., Marzinke, M. A., Hendrix, C. W., Beliveau, M., Moss, J. A., Smith, T. J., & Baum, M. M. (2015). Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrobial Agents and Chemotherapy, 59(7), 3913–3919. https://doi.org/10.1128/AAC.00656-15
- Hassounah, S. A., & Mesplède, T. (2018). Where are we with injectables against HIV infection and what are the remaining challenges? Expert Review of Anti-Infective Therapy, 16(2), 143–152. https://doi.org/10.1080/14787210.2018.1430570
- Iacob, S. A., Iacob, D. G., & Jugulete, G. (2017). Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Frontiers in Pharmacology, 8, 831. https://doi.org/10.3389/fphar.2017.00831
- Janz, N. K., & Becker, M. H. (1984). The health belief model: A decade later. Health Education Quarterly, 11(1), 1–47. https://doi.org/10.1177/109019818401100101
- Kerrigan, D., Mantsios, A., Gorgolas, M., Montes, M. L., Pulido, F., Brinson, C., deVente, J., Richmond, G. J., Beckham, S. W., Hammond, P., Margolis, D., & Murray, M. (2018). Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One, 13(1), e0190487. https://doi.org/10.1371/journal.pone.0190487
- Kroenke, K., Spitzer, R. L., Williams, J. B., & Löwe, B. (2009). An ultra-brief screening scale for anxiety and depression: The PHQ-4. Psychosomatics, 50(6), 613–621. https://doi.org/10.1176/appi.psy.50.6.613
- Kroenke, K., Spitzer, R. L., Williams, J. B., & Löwe, B. (2010). The patient health questionnaire somatic, anxiety, and depressive symptom scales: A systematic review. General Hospital Psychiatry, 32(4), 345–359. https://doi.org/10.1016/j.genhosppsych.2010.03.006
- Levy, M. E., Patrick, R., Gamble, J., Rawls, A., Opoku, J., Magnus, M., Kharfen, M., Greenberg, A. E., Kuo, I., & Colby, D. J. (2017). Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis. PLoS One, 12(8), e0183521. https://doi.org/10.1371/journal.pone.0183521
- Maggiolo, F., Ripamonti, D., Arici, C., Gregis, G., Quinzan, G., Camacho, G. A., Ravasio, L., & Suter, F. (2002). Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clinical Trials, 3(5), 371–378. https://doi.org/10.1310/hct.2002.3.5.004 doi: 10.1310/98B3-PWG8-PMYW-W5BP
- Margolis, D. A., Gonzalez-Garcia, J., Stellbrink, H. J., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., Lutz, T., Angel, J. B., Richmond, G. J., Clotet, B., Gutierrez, F., Sloan, L., Clair, M. S., Murray, M., Ford, S. L., Mrus, J., Patel, P., Crauwels, H., Griffith, S. K., … Spreen, W. R. (2017). Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. The Lancet, 390(10101), 1499–1510. https://doi.org/10.1016/S0140-6736(17)31917-7
- Meyers, K., Rodriguez, K., Moeller, R. W., Gratch, I., Markowitz, M., & Halkitis, P. N. (2014). High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: A P18 cohort substudy. PLoS One, 9(12), e114700. https://doi.org/10.1371/journal.pone.0114700
- Mimiaga, M. J., Case, P., Johnson, C. V., Safren, S. A., & Mayer, K. H. (2009). Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: Limited knowledge and experience but potential for increased utilization after education. JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(1), 77–83. https://doi.org/10.1097/QAI.0b013e31818d5a27
- Nachega, J. B., Parienti, J. J., Uthman, O. A., Gross, R., Dowdy, D. W., Sax, P. E., Gallant, J. E., Mugavero, M. J., Mills, E. J., & Giordano, T. P. (2014). Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clinical Infectious Diseases, 58(9), 1297–1307. https://doi.org/10.1093/cid/ciu046
- Nyaku, A. N., Kelly, S. G., & Taiwo, B. O. (2017). Long-acting antiretrovirals: Where are we now? Current HIV/AIDS Reports, 14(2), 63–71. https://doi.org/10.1007/s11904-017-0353-0
- Oremus, M., Cosby, J. L., & Wolfson, C. (2005). A hybrid qualitative method for pretesting questionnaires: The example of a questionnaire to caregivers of Alzheimer disease patients. Research in Nursing & Health, 28(5), 419–430. https://doi.org/10.1002/nur.20095
- Parsons, J. T., Rendina, H. J., Whitfield, T. H., & Grov, C. (2016). Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S. AIDS and Behavior, 20(7), 1390–1399. https://doi.org/10.1007/s10461-016-1370-5
- Rusconi, S., Marcotullio, S., & Cingolani, A. (2017). Long-acting agents for HIV infection: Biological aspects, role in treatment and prevention, and patient’s perspective. The New Microbiologica, 40(2), 75–79.
- Swindells, S., Andrade-Villanueva, J.-F., Richmond, G. J., Rizzardini, G., Baumgarten, A., Masia, M. D. M., … Spreen, W. (March 4–7, 2019). Long acting Cabotegravir + Rilpivirine as maintenance therapy: ATLAS Week 48 Results. Paper presented at the CROI, Seattle, Washington.
- Understanding the HIV Care Continuum. (July 2017). HIV fact sheets. https://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf
- Weld, E. D., Rana, M. S., Dallas, R. H., Camacho-Gonzalez, A. F., Ryscavage, P., Gaur, A. H., Chakraborty, R., Swindells, S., Flexner, C., & Agwu, A. L. (2018). Interest of youth living with HIV in long-acting antiretrovirals. JAIDS Journal of Acquired Immune Deficiency Syndromes, https://doi.org/10.1097/QAI.0000000000001896
- Weld, E. D., Rana, M. S., Dallas, R. H., Camacho-Gonzalez, A. F., Ryscavage, P., Gaur, A. H., Chakraborty, R., Swindells, S., Flexner, C., & Agwu, A. L. (2019). Interest of youth living with HIV in long-acting antiretrovirals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 80(2), 190–197. https://doi.org/10.1097/QAI.0000000000001896
- Williams, J., Sayles, H. R., Meza, J. L., Sayre, P., Sandkovsky, U., Gendelman, H. E., Flexner, C., & Swindells, S. (2013). Long-acting parenteral nanoformulated antiretroviral therapy: Interest and attitudes of HIV-infected patients. Nanomedicine (Lond), 8(11), 1807–1813. https://doi.org/10.2217/nnm.12.214
- Wilson, I. B., Lee, Y., Michaud, J., Fowler, F. J., & Rogers, W. H. (2016). Validation of a new three-item self-report measure for medication adherence. AIDS and Behavior, 20(11), 2700–2708. https://doi.org/10.1007/s10461-016-1406-x